Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics (NASDAQ:VYGR), a biotechnology company focused on neurological diseases, has announced its participation in six major investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Voyager Therapeutics (NASDAQ:VYGR), a biotechnology company focused on neurological diseases, has announced its participation in six major investor conferences in September 2025. The company will present at the Citi Biopharma, Wells Fargo Healthcare, Cantor Global Healthcare, Morgan Stanley Global Healthcare, Baird Global Healthcare, and H.C. Wainwright Global Investment conferences.
During these presentations, Voyager plans to discuss its non-viral delivery platform and novel receptor-binding molecules for transporting neurotherapeutics across the blood-brain barrier. Webcasts for the Citi and Baird presentations will be available on the company's investor relations website for at least 30 days.
Details
News Market Reaction – VYGR
On Aug 26, the day this news came out, VYGR closed 2.40% above the previous close.
Data tracked by StockTitan Argus for the Aug 26 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:
- Citi's 2025 Biopharma Back to School Conference: Fireside chat at 4:00 p.m. ET on Tuesday, September 2, 2025, in Boston, MA, during which the company plans to highlight preclinical data supporting its non-viral delivery platform leveraging novel receptor-binding molecules to transport multiple modalities of neurotherapeutics across the blood-brain barrier.
- 2025 Wells Fargo Healthcare Conference: Fireside chat at 4:30 p.m. ET on Wednesday, September 3, 2025, in Boston, MA.
- Cantor Global Healthcare Conference 2025: Fireside chat at 1:35 p.m. ET on Thursday, September 4, 2025, in New York, NY.
- Morgan Stanley 23rd Annual Global Healthcare Conference: Available for one-on-one meetings on Monday, September 8, 2025, in New York, NY.
- Baird 2025 Global Healthcare Conference: Fireside chat at 9:05 a.m. ET on Tuesday, September 9, 2025, in New York, NY.
- H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat at 2:30 p.m. ET on Tuesday, September 9, 2025, in New York, NY.
Webcasts of the Citi and Baird fireside chats will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of these two webcasts will be archived on the company’s website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Sarah McCabe, smccabe@jpa.com
Media: Adam Silverstein, adam@scientpr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.